• Tatjana S Potpara, Gheorghe-Andrei Dan, Elina Trendafilova, Artan Goda, Zumreta Kusljugic, Sime Manola, Ljilja Music, Rodica Musetescu, Elisabeta Badila, Gorana Mitic, Vilma Paparisto, Elena S Dimitrova, Marija M Polovina, Stanislav L Petranov, Hortensia Djergo, Daniela Loncar, Amira Bijedic, Sandro Brusich, Gregory Y H Lip, and BALKAN-AF Investigators.
• School of Medicine, Belgrade University, Belgrade, Serbia.
• Sci Rep. 2016 Feb 12; 6: 20432.

AbstractData on the management of atrial fibrillation (AF) in the Balkan Region are limited. The Serbian AF Association (SAFA) prospectively investigated contemporary 'real-world' AF management in clinical practice in Albania, Bosnia&Herzegovina, Bulgaria, Croatia, Montenegro, Romania and Serbia through a 14-week (December 2014-February 2015) prospective, multicentre survey of consecutive AF patients. We report the results pertinent to stroke prevention strategies. Of 2712 enrolled patients, 2663 (98.2%) with complete data were included in this analysis (mean age 69.1 ± 10.9 years, female 44.6%). Overall, 1960 patients (73.6%) received oral anticoagulants (OAC) and 762 (28.6%) received antiplatelet drugs. Of patients given OAC, 17.2% received non-vitamin K antagonist oral anticoagulants (NOACs). CHA2DS2-VASc score was not significantly associated with OAC use. Of the 'truly low-risk' patients (CHA2DS2-VASc = 0 [males], or 1 [females]) 56.5% received OAC. Time in Therapeutic Range (TTR) was available in only 18.7% of patients (mean TTR: 49.5% ± 22.3%). Age ≥ 80 years, prior myocardial infarction and paroxysmal AF were independent predictors of OAC non-use. Our survey shows a relatively high overall use of OAC in AF patients, but with low quality of vitamin K antagonist therapy and insufficient adherence to AF guidelines. Additional efforts are needed to improve AF-related thromboprophylaxis in clinical practice in the Balkan Region.

32 keywords...

hide…